Atavistik Bio Partners with Pfizer to Discover Novel Precision Allosteric Therapeutics
Shots:
- Atavistik Bio has signed a research collaboration with Pfizer to discover novel precision allosteric therapies for significant unmet medical needs
- As per the terms, Atavistik Bio will identify allosteric binders for Pfizer’s 2 undisclosed targets, with Pfizer having the option to license the programs post research. Financial terms are undisclosed
- The alliance will expand the reach of AMPS platform, targeting various oncology indications while also advancing its precision oncology small molecule pipeline. The platform uses integrated computational and experimental techniques to design small molecules for challenging targets
Ref: Atavistik | Image: Atavistik & Pfizer
Related News:- Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
